Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 21 - 30 of 44 results.

You searched for : August 2018 to August 2019.

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartin ...

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor Download the PDF version of...

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed” Download the PDF version of Article January 29, 2019 Carrie Ann Inaba shares her personal journey...

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 L ...

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer Download the PDF version of Article January 14, 2019 DESTINY-Breast04...

Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within i ...

Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML Download the PDF version of Article December 19, 2018 Phase...

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics Download the PDF version of Article December 17, 2018 Tokyo, Japan, Basking Ridge, NJ, and New York, NY – (December...

Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel ...

Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies Download the PDF version of Article December 10, 2018 Nashville, Tenn., Tokyo,...

Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patie ...

Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium...

Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastati ...

Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS) Download the PDF version of...

Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival ...

Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival Benefit of Daiichi Sankyo’s FLT3 Inhibitor Quizartinib in Patients with Relapsed/Refractory...

Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test

Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test Download the PDF version of Article November 27, 2018 Tokyo, Munich, Basking Ridge, NJ– (November 27, 2018) –...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...